PIK-90 - CAS 677338-12-4
Catalog number: 677338-12-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H17N5O3
Molecular Weight:
351.366
COA:
Inquire
Targets:
PI3K
Description:
PIK-90 is a potent PI3K inhibitor.
Purity:
0.98
Synonyms:
PIK-90; PIK90; PIK 90.
MSDS:
Inquire
InChIKey:
ZJAVHOMVDCMAMF-UHFFFAOYSA-N
InChI:
InChI=1S/C18H17N5O3/c1-25-13-6-5-12-14(15(13)26-2)21-18(23-9-8-20-16(12)23)22-17(24)11-4-3-7-19-10-11/h3-7,10H,8-9H2,1-2H3,(H,21,22,24)
Canonical SMILES:
COC1=C(C2=C(C=C1)C3=NCCN3C(=N2)NC(=O)C4=CN=CC=C4)OC
1.Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.
Cheng CK1, Gustafson WC, Charron E, Houseman BT, Zunder E, Goga A, Gray NS, Pollok B, Oakes SA, James CD, Shokat KM, Weiss WA, Fan QW. Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12722-7. doi: 10.1073/pnas.1202492109. Epub 2012 Jul 16.
Malignant glioma, the most common primary brain tumor, is generally incurable. Although phosphatidylinositol-3-kinase (PI3K) signaling features prominently in glioma, inhibitors generally block proliferation rather than induce apoptosis. Starting with an inhibitor of both lipid and protein kinases that induced prominent apoptosis and that failed early clinical development because of its broad target profile and overall toxicity, we identified protein kinase targets, the blockade of which showed selective synthetic lethality when combined with PI3K inhibitors. Prioritizing protein kinase targets for which there are clinical inhibitors, we demonstrate that cyclin-dependent kinase (CDK)1/2 inhibitors, siRNAs against CDK1/2, and the clinical CDK1/2 inhibitor roscovitine all cooperated with the PI3K inhibitor PIK-90, blocking the antiapoptotic protein Survivin and driving cell death. In addition, overexpression of CDKs partially blocked some of the apoptosis caused by PIK-75.
2.A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
Fan QW1, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM, Weiss WA. Cancer Res. 2007 Sep 1;67(17):7960-5.
We have shown previously that blockade of epidermal growth factor receptor (EGFR) cooperates with a pan-selective inhibitor of phosphoinositide-3-kinase (PI3K) in EGFR-driven glioma. In this communication, we tested EGFR-driven glioma differing in PTEN status, treating with the EGFR inhibitor erlotinib and a novel dual inhibitor of PI3Kalpha and mTOR (PI-103). Erlotinib blocked proliferation only in PTEN(wt) cells expressing EGFR. Although erlotinib monotherapy showed little effect in PTEN(mt) glioma, PI-103 greatly augmented the antiproliferative efficacy of erlotinib in this setting. To address the importance of PI3K blockade, we showed in PTEN(mt) glioma that combining PI-103 and erlotinib was superior to either monotherapy or to therapy combining erlotinib with either rapamycin (an inhibitor of mTOR) or PIK-90 (an inhibitor of PI3Kalpha). These experiments show that a dual inhibitor of PI3Kalpha and mTOR augments the activity of EGFR blockade, offering a mechanistic rationale for targeting EGFR, PI3Kalpha, and mTOR in the treatment of EGFR-driven, PTEN-mutant glioma.
3.Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
Zhang TT1, Okkenhaug K, Nashed BF, Puri KD, Knight ZA, Shokat KM, Vanhaesebroeck B, Marshall AJ. J Allergy Clin Immunol. 2008 Oct;122(4):811-819.e2. doi: 10.1016/j.jaci.2008.08.008.
BACKGROUND: Recent studies indicate that pharmaceutical blockade of phosphoinositide 3-kinase (PI3K) signaling enzymes might be effective in reducing allergic airway inflammation. Signals generated by the p110delta PI3K isoform play critical roles in signaling through antigen and cytokine receptors and were shown to be required for induction of type 2, but not type 1, cytokine responses.
4.Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Niedermeier M1, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Blood. 2009 May 28;113(22):5549-57. doi: 10.1182/blood-2008-06-165068. Epub 2009 Mar 24.
Phosphoinositide 3-kinases (PI3Ks) are among the most frequently activated signaling pathways in cancer. In chronic lymphocytic leukemia (CLL), signals from the microenvironment are critical for expansion of the malignant B cells, and cause constitutive activation of PI3Ks. CXCR4 is a key receptor for CLL cell migration and adhesion to marrow stromal cells (MSCs). Because of the importance of CXCR4 and PI3Ks for CLL-microenvironment cross-talk, we investigated the activity of novel, isoform-selective PI3K inhibitors that target different isoforms of the p110-kDa subunit. Inhibition with p110alpha inhibitors (PIK-90 and PI-103) resulted in a significant reduction of chemotaxis and actin polymerization to CXCL12 and reduced migration beneath MSC (pseudoemperipolesis). Western blot and reverse phase protein array analyses consistently demonstrated that PIK-90 and PI-103 inhibited phosphorylation of Akt and S6, whereas p110delta or p110beta/p110delta inhibitors were less effective.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PI3K Products


CAS 1236188-16-1 740 Y-P

740 Y-P
(CAS: 1236188-16-1)

740 Y-P is a cell-permeable phosphopeptide activator of PI3K. It binds to the p85 N- and C-terminal SH2 domains of PI3K but not to GST or the N-terminal domain ...

CAS 870281-82-6 CAL-101 (GS-1101)

CAL-101 (GS-1101)
(CAS: 870281-82-6)

Idelalisib is a kinase inhibitor. In combination with rituximab, it was used for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).

CAS 1372540-25-4 GSK2636771

GSK2636771
(CAS: 1372540-25-4)

GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineopla...

CAS 1218777-13-9 CAY10505

CAY10505
(CAS: 1218777-13-9)

CAY10505 is a phosphatidylinositol 3-kinase-γ inhibitor, was found to significantly improve acetylcholine-induced endothelium dependent relaxation, serum nitrat...

CAS 1032568-63-0 Copanlisib

Copanlisib
(CAS: 1032568-63-0)

Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BAY 80-6946 inhibits the activation of the PI3K signaling pat...

CAS 1166227-08-2 A66

A66
(CAS: 1166227-08-2)

Inhibition of p110α alone by A66 treatment is sufficient to block insulin signalling to Akt/PKB in certain cell lines that harbor H1047R mutations in PIK3CA and...

AM-9635
(CAS: 1338483-10-5)

AM-9635 is a selective Phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor. AM-9635 exhibits good cellular potency (in vitro pAKT IC50 = 4.2 nM ). AM-9635 can...

CAS 1276553-09-3 PF-4989216

PF-4989216
(CAS: 1276553-09-3)

PF-4989216 is a novel potent and selective PI3K inhibitor. PF-4989216 inhibits the phosphorylation of PI3K downstream molecules and subsequently leads to inhib...

Chemical Structure

CAS 677338-12-4 PIK-90

Quick Inquiry

Verification code

Featured Items